WO2011156000A3 - Use of il-4/il-13 antagonists to treat eosinophilic disorders - Google Patents

Use of il-4/il-13 antagonists to treat eosinophilic disorders Download PDF

Info

Publication number
WO2011156000A3
WO2011156000A3 PCT/US2011/001050 US2011001050W WO2011156000A3 WO 2011156000 A3 WO2011156000 A3 WO 2011156000A3 US 2011001050 W US2011001050 W US 2011001050W WO 2011156000 A3 WO2011156000 A3 WO 2011156000A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
eosinophic
provides methods
disorders
eosinophilic disorders
Prior art date
Application number
PCT/US2011/001050
Other languages
French (fr)
Other versions
WO2011156000A2 (en
Inventor
Babatunde Otulana
Original Assignee
Aerovance, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerovance, Inc. filed Critical Aerovance, Inc.
Publication of WO2011156000A2 publication Critical patent/WO2011156000A2/en
Publication of WO2011156000A3 publication Critical patent/WO2011156000A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13

Abstract

The present invention provides methods for treating eosinophic disorders, including eosinophic asthma, by administering compositions that act as antagonists to IL 4 and IL-13, in particular antisense, RNAi, antibody, and mutant human interleukin-4 (IL-4) antagonists. The invention also provides methods and kits for determining the major allele in certain SNPs in the IL-4 receptor α polypeptide (IL-4RA) as an indication of likely response to IL-4/IL-13 antagonist treatment.
PCT/US2011/001050 2010-06-07 2011-06-07 Use of il-4/il-13 antagonists to treat eosinophilic disorders WO2011156000A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39717410P 2010-06-07 2010-06-07
US61/397,174 2010-06-07

Publications (2)

Publication Number Publication Date
WO2011156000A2 WO2011156000A2 (en) 2011-12-15
WO2011156000A3 true WO2011156000A3 (en) 2013-11-07

Family

ID=45098570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/001050 WO2011156000A2 (en) 2010-06-07 2011-06-07 Use of il-4/il-13 antagonists to treat eosinophilic disorders

Country Status (1)

Country Link
WO (1) WO2011156000A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230167770A (en) * 2014-02-21 2023-12-11 사노피 바이오테크놀로지 Methods for treating or preventing asthma by administering an il-4r antagonist
MX2016013372A (en) * 2014-04-11 2017-01-26 Novartis Ag Methods of selectively treating asthma using il-13 antagonists.
US9815894B2 (en) * 2014-09-08 2017-11-14 Cephalon, Inc. Use of reslizumab to treat moderate to severe eosinophilic asthma
US20230151426A1 (en) * 2021-09-30 2023-05-18 Regeneron Pharmaceuticals, Inc. Reticulocalbin-3 (RCN3) Variants And Treatment Of Asthma With Interleukin-4 Receptor Alpha (IL4R) Antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090010874A1 (en) * 2003-08-29 2009-01-08 Aerovance, Inc. Modified il-4 mutein receptor antagonists
US20090291981A1 (en) * 2008-05-23 2009-11-26 Amira Pharmaceuticals, Inc. 5-Lipoxygenase-Activating Protein Inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090010874A1 (en) * 2003-08-29 2009-01-08 Aerovance, Inc. Modified il-4 mutein receptor antagonists
US20090291981A1 (en) * 2008-05-23 2009-11-26 Amira Pharmaceuticals, Inc. 5-Lipoxygenase-Activating Protein Inhibitor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BORISH, L.C. ET AL.: "Efficacy Of Soluble IL-4 Receptor For The Treatment Of Adults With Asthma", J ALLERGY CLIN IMMUNOL., vol. 107, no. 6, June 2001 (2001-06-01), pages 963 - 970 *
LECKIE, M.J. ET AL.: "Effects Of An Interleukin-5 Blocking Monoclonal Antibody On Eosinophils, Airway Hyper-Responsiveness, And The Late Asthmatic Response", THE LANCET, vol. 356, 23 December 2000 (2000-12-23), pages 2144 - 2148 *
UMHS ASTHMA QUALITY IMPROVEMENT STEERING COMMITTEE: "Quick Reference Charts For The Classification And Stepwise Treatment Of Asthma", ADAPTED FROM 2007 NHLBI GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF ASTHMA EXPERT PANEL REPORT 3, 30 June 2008 (2008-06-30) *
YING, S. ET AL.: "Associations Between IL-13 And IL-4 (mRNA And Protein), Vascular Cell Adhesion Molecule-1 Expression, And The Infiltration Of Eosinophils, Macrophages, And T Cells In Allergen-Induced Late-Phase Cutaneous Reactions In Atopic Subjects", THE JOURNAL OF IMMUNOLOGY, vol. 158, no. 10, 10 February 1997 (1997-02-10), pages 5050 - 5057 *

Also Published As

Publication number Publication date
WO2011156000A2 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
WO2013033626A3 (en) Nkp30 receptor targeted therapeutics
NZ756750A (en) Methods and compositions comprising purified recombinant polypeptides
EP4324479A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MX2019002344A (en) Methods for preventing or treating allergy by administering an il-4r antagonist.
WO2012118750A3 (en) Biological markers and methods for predicting response to b-cell antagonists
MX354666B (en) Antibodies that bind il-4 and/or il-13 and their uses.
MX2014006158A (en) Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles.
NZ588853A (en) Compositions and methods for treating and diagnosing asthma
WO2007082068A3 (en) Methods and compositions for treating asthma in human and non human primates
MX2008010807A (en) Thymic stromal lympho po i et in (tslp) antibodies and uses thereof.
MX2018009524A (en) Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use.
WO2013067451A3 (en) Methods and compositions for diagnosing, prognosing, and treating neurological conditions
TW200716171A (en) Methods for treating and preventing fibrosis
MX2013008833A (en) Methods and compositons relating to inhibition of igf-1r.
EA201100150A1 (en) TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASE
WO2008060813A3 (en) High affinity antibody antagonists of interleukin-13 receptor alpha 1
MY144906A (en) Human antibodies against il13 and therapeutic uses
TW200736274A (en) Immunoglobulins
MY158927A (en) Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
EP2523678A4 (en) Wnt antagonists and methods of treatment and screening
MY156337A (en) Agonist dr5 binding polypeptides
WO2011156000A3 (en) Use of il-4/il-13 antagonists to treat eosinophilic disorders
EP2563794A4 (en) Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
MX2010010799A (en) Methods of diagnosing, preventing and treating bone mass diseases.
WO2011128820A3 (en) Methods for the analysis of breast cancer disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11792785

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 03/06/2013)

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 13/02/2013)

122 Ep: pct application non-entry in european phase

Ref document number: 11792785

Country of ref document: EP

Kind code of ref document: A2